COMP <GO>
SYK vs LLY // ALTMAN Z-SCORE & DEBT/EQUITY
Stryker Corporation (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: SYK 4
— LLY 10
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: LLY
LAST: $291.86 (-6.38%) • MKT CAP: $119.58B
balance-sheet
4.46
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
balance-sheet
9.29
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SYK VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SYK | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.00% | 83.64% | -19.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.60% | 32.36% | -20.76 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 23.6x | 36.4x | -12.82 | SYK | /valuation <GO> |
| Free Cash Flow Yield | 3.58% | 2.30% | +1.28 | SYK | /fcf-yield <GO> |
| Operating Margin | 19.50% | 40.21% | -20.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 12.90% | 31.90% | -19.00 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 11.20% | 45.51% | -34.31 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.07% | 0.49% | +0.58 | SYK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 4.46 | 9.29 | -4.83 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.77% | +0.53 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.0 | 77.9 | -29.90 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.13 | 0.51 | +0.62 | SYK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.2x | 26.3x | +7.95 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $119.58B | $1.33T | -$1.21T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SYK REV | LLY REV | SYK GROSS % | LLY GROSS % | SYK FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $25.12B | $65.18B | 64.0% | 83.0% | $4.28B | $16.81B |
| FY 2024 | $22.59B | $45.04B | 63.9% | 81.3% | $3.49B | $8.82B |
| FY 2023 | $20.50B | $34.12B | 44.0% | 79.3% | $2.79B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SYK // BETA 1.13
LLY // BETA 0.51